Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 250

COMPASS study presented at ESC Congress 2017 – largest rivaroxaban study to date

Posted by fidest press agency su mercoledì, 30 agosto 2017

bayer_healthcareBayer and its cooperation partner Janssen Research & Development, LLC, today announced results at The European Society of Cardiology (ESC) Congress that are set to change clinical practice in the UK for cardiologists treating patients with coronary artery disease (CAD) and peripheral artery disease (PAD). Highly anticipated Phase III COMPASS study data announced during two hot line presentations at ESC in Barcelona, and simultaneously published in The New England Journal of Medicine, showed Bayer’s Factor Xa inhibitor, rivaroxaban (Xarelto®) vascular dose, (2.5 mg twice daily), plus aspirin 100 mg once daily, reduced the risk of the composite endpoint of stroke, cardiovascular (CV) death and heart attack by 24% (relative risk reduction, ARR: 1.3%) in patients with CAD and PAD1. The study compared this combined approach with aspirin 100 mg once daily alone. Patients included in the study already received guideline recommended therapy for hypertension, high cholesterol and diabetes. A 5 mg twice daily dose of rivaroxaban was also investigated but did not reach statistical significance.
Coronary artery disease (CAD) is the most common cause of cardiovascular disease and is estimated to occur in up to 20-30% of patients with AF3. It is responsible for approximately 7.3 million deaths worldwide every year, with up to half of all middle-aged men and women at risk of developing CAD during their lifetime5. The number of patients with AF and CAD that will have to undergo coronary revascularisation has doubled in the last decade6. Peripheral artery disease (PAD), while often undiagnosed, affects over 27 million people in Europe and North America and is an important risk marker of cardiovascular diseas.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di

Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: